RecruitingPhase 2

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

United States45 participantsStarted 2023-12-20

Plain-language summary

This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Estimated glomerular filtration rate of \<30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equations
✕. WBC count \<4 × 109/L
✕. Absolute lymphocyte count \<500 cells/mm3
✕. Absolute neutrophil count \<1000 cells/mm3
✕. Platelet count \<120,000/mm3
✕. Hemoglobin \<8 g/dL (\<80 g/L)

The proportion of subjects in remission [OGC 4.0]

Timeframe: From Baseline to week 28

NCT IDNCT06046222

SponsorNS Pharma, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-06

NS Pharma, Inc.